Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial
- 25 January 2015
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 385 (9981), 1957-1965
- https://doi.org/10.1016/s0140-6736(14)61942-5
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trialEuropean Heart Journal, 2013
- Renal Sympathetic Denervation for Treatment of Drug-Resistant HypertensionCirculation, 2012
- Renal DenervationHypertension, 2012
- Sequential nephron blockade versus sequential renin–angiotensin system blockade in resistant hypertensionJournal of Hypertension, 2012
- ESH Position PaperJournal of Hypertension, 2012
- Catheter-based Radiofrequency Renal-nerve Ablation in Patients with Resistant HypertensionEuropean Journal of Vascular and Endovascular Surgery, 2012
- Management of hypertension: summary of NICE guidanceBMJ, 2011
- Setting-up a Blood Pressure and Vascular Protection Clinic: Requirements of the European Society of HypertensionJournal of Hypertension, 2010
- Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurementsJournal of Hypertension, 2003
- The Ethical Problems with Sham Surgery in Clinical ResearchThe New England Journal of Medicine, 1999